Addition of the malate salt at 2.0–3.5 wt% relative to total formulation mass has been adopted on direct-compression lines to control Carr’s Index values below 25 when targeting 12.5 mg, 25 mg, and 50 mg capsule dose strengths. Pre-blending the compound with pregelatinized starch (Starch 1500) and lactose monohydrate (spray-dried, D50 75 µm) in a bin blender running at 15 rpm for 200 revolutions achieves blend homogeneity with relative standard deviation (RSD) below 5.0% as verified by stratified sampling under ASTM E2810-19. Excipient compatibility studies conducted via isothermal microcalorimetry at 40 °C/75% RH over 14 days reveal no exothermic deviation exceeding 2.0 µW/g for anhydrous dibasic calcium phosphate or mannitol SD 200, whereas reducing sugars induce a broad endotherm shift indicative of Maillard adduct formation—such combinations are explicitly avoided. Compression force is maintained between 8 kN and 14 kN on a rotary press fitted with size 3 tooling; ejection force must not exceed 300 N to prevent lamination defects. Terminal sterilization via gamma irradiation is contraindicated due to a 0.15% increase in total related substances per 10 kGy as quantified by UPLC at 254 nm. Instead, bioburden control is achieved through pre-irradiated excipients and terminal 0.22 µm sterile filtration of the blending area. The finished capsule product is restricted to immediate-release dissolution profiles conforming to USP monograph 1972, with Q ≥ 80% at 30 minutes in 0.1 N HCl containing 2.0% sodium lauryl sulfate at 37 °C.
What Prevents Norrish-Type Photodegradation During Isolation of the Free-Base Intermediate?
Light-induced Z-to-E isomerization at the C3-exocyclic double bond and subsequent photo-oxidation at the indolin-2-one carbonyl define the primary degradation routes detectable under ICH Q1B Option 2 illumination. Isolation protocols executed in amber-glass reactors at illuminance below 1,500 lux preserve Z-isomer integrity at >99.2% as confirmed by HPLC retention-time alignment vs. a pharmacopoeial reference standard. The free base is precipitated from a tetrahydrofuran:water system (70:30 v/v) at 5 °C with a controlled anti-solvent addition rate of 2.0 mL/min, generating a crystalline form consistent with Form I (PXRD peaks at 2θ = 12.42°, 14.46°, and 22.18°). Residual palladium from Suzuki-Miyaura coupling steps must be reduced to 10 ppm or below via charcoal (Darco KB-B, 0.5 wt%) treatment at 60 °C for 2 hours, monitored by ICP-MS following USP <232> procedures, because Pd(0) microparticles facilitate catalytic photodegradation exceeding ICH Q3D parenteral elemental impurity limits. The purified free base exhibits a melting endotherm at 248–252 °C (DSC, 10 °C/min) with a heat of fusion between 95–105 J/g; deviation below this range indicates amorphous content above 5.0% that compromises oxidative stability over a 24-month ICH Q1A shelf-life window.
During Twin-Screw Wet Granulation for Immediate-Release Tablets
Granulating the compound with a 6.0 wt% povidone K30 binder solution introduced at a liquid-to-solid ratio of 0.35 in a co-rotating twin-screw extruder (L/D 25:1) produces granules with a D50 of 220–280 µm when screw speed is locked at 400 rpm and barrel temperature segments are held at 25 °C/30 °C/35 °C. Torque values exceeding 12 N·m indicate over-granulation; corrective action involves increasing feed rate by 15% to reduce residence time below 30 seconds. The dried granules (LOD < 1.5%) are blended with croscarmellose sodium (4.0 wt%, intra-granular) and sodium stearyl fumarate (1.2 wt%, extragranular), avoiding magnesium stearate entirely because Mg2+ ions coordinate with the morpholine tertiary amine and catalyze deprotonation-linked discoloration under accelerated stability conditions (40 °C/75% RH). Tablet hardness is maintained between 60 N and 90 N, allowing friability below 0.8% after 100 drops in a Roche friabilator (USP <1216>). Bioequivalence risk arises if the granule dissolution RSD crosses 10% at the 15-minute sampling interval—a threshold requiring mesh-screening of oversized granules before final compression.
Intravenous administration development involves conversion of the base to a phosphate-buffered lyophilized cake at a target concentration of 5.0 mg/mL upon reconstitution with Water for Injection. A co-solvent system comprising polyethylene glycol 400 (15% v/v) and ethanol anhydrous (5.0% v/v) is used to dissolve the compound at 10.0 mg/mL before sterile filtration through a 0.22 µm PVDF membrane; filter compatibility testing must demonstrate 98.0% recovery per USP <1663> to exclude adsorptive losses to the membrane matrix. The solution is filled into Type I glass vials and subjected to lyophilization with a primary drying shelf temperature of -25 °C at 100 mTorr for 48 hours, followed by secondary drying at 25 °C until Karl Fischer moisture reads below 1.0%. Rejection of visible sub-visible particulates per USP <787> requires that the reconstituted solution contain no more than 6,000 particles per vial at ≥ 10 µm and 600 particles at ≥ 25 µm. Use of citrate buffer in place of phosphate is incompatible, producing a lipophilic ion-pair complex that crystallizes as visible needles within 6 hours at 5 °C. Sterile 0.9% sodium chloride diluent for infusion must be PS80-free; polysorbate 80 at concentrations above 0.01% micellizes the compound and alters distribution volume in a xenograft PK model.
| Parameter | Form I (Stable) | Form II (Metastable) |
|---|---|---|
| Melting Onset (DSC) | 239–242 °C | 225–230 °C |
| Equilibrium Solubility in pH 6.8 Phosphate Buffer | 2.8 µg/mL | 4.1 µg/mL |
| Intrinsic Dissolution Rate (USP <1087>, 37 °C, 100 rpm) | 0.031 mg·cm⁻²·min⁻¹ | 0.058 mg·cm⁻²·min⁻¹ |
| Slurry Conversion Time to Form I in Acetone | Stable | <8 h at 25 °C |
Targeting pancreatic neuroendocrine tumor xenograft studies, microencapsulation in poly(lactic-co-glycolic acid) (PLGA, 50:50, inherent viscosity 0.38 dL/g) is performed by a single-emulsion (O/W) solvent evaporation method. The compound is dissolved in dichloromethane at 50 mg/mL and emulsified into a 1.0% w/v polyvinyl alcohol aqueous phase using a rotor-stator homogenizer at 15,000 rpm for 60 seconds. Microspheres sized between 20 µm and 60 µm with a span value < 1.2 (Malvern Mastersizer) are collected after solvent evaporation at 25 °C for 4 hours under 500 rpm magnetic stirring. Encapsulation efficiency determined by acetonitrile extraction followed by HPLC at 431 nm exceeds 85% only when the drug:polymer ratio is kept below 1:8; higher loadings induce surface crystallization and a triphasic release profile unacceptable for once-monthly depot development. Residual dichloromethane is reduced to 600 ppm or less (ICH Q3C Option 2 limit) by vacuum post-drying at 30 °C for 24 hours. Gamma-sterilized microspheres at 25 kGy exhibit 2.0% crosslinking-associated decrease in burst release and unchanged total cumulative release over 28 days in PBS at 37 °C, as verified by USP apparatus 4 flow-through cell.
Residue Control in a Cytotoxic Cleanroom Configuration
Occupational exposure band (OEB) 4 containment is mandated because the compound inhibits VEGFR-2 with an IC50 below 10 nM, triggering potential reproductive and developmental toxicity under the GHS hazard classification (H360D, H373). Shifting from open-transfer filtration to single-use closed-system isolators fitted with α/β ports eliminates detectable surface contamination by monitoring with HPLC-MS/MS validated to a limit of quantification of 10 ng/cm² per ASTM D7822-18. Deactivation of facility reject streams uses a 1.0% sodium hypochlorite solution at pH 10.0 with a contact time of 30 minutes, achieving >99.9% degradation of the fluorinated indolinone chromophore as monitored by UV absorbance loss at 364 nm. Analytical method transfer from R&D to the quality control line enforces a purity acceptance criterion of ≥ 99.0% by area normalization and single unknown impurity not exceeding 0.10% per ICH Q3A (Threshold ID = 0.10% for a 2.0 g daily dose). Process water generated during decontamination must not be discharged without pre-treatment—activated carbon beds with 2.0% w/w adsorption capacity relative to compound mass are validated with 3 breakthrough cycles before replacement.
In Vitro Kinase Panel Profiling and Calibration Standard Usage
When the free base is employed as a reference inhibitor in biochemical ADP-Glo™ kinase assays against VEGFR-2 (aa 789-1356) and PDGFR-β (aa 557-1106), a 10 mM DMSO stock solution is pre-dried to an amorphous film and reconstituted in assay buffer containing 50 mM HEPES pH 7.5, 10 mM MgCl₂, 1.0 mM EGTA, 0.01% Brij-35, and 2.0% final DMSO to avoid kinase denaturation. Serial dilutions from 1.0 µM to 0.1 nM (half-log steps) enable IC50 curve fitting with a Hill slope between -0.9 and -1.2 for acceptable data sets; deviation flags compound aggregation, which is precluded by adding 0.01% v/v Tween-20 as a dispersant. The compound’s fluorescence quantum yield at 431/540 nm interferes with time-resolved FRET platforms unless signal crosstalk correction factors (CCF) below 0.5% are applied. Purity of the calibration standard must be verified by quantitative NMR (qNMR) with maleic acid as an internal standard, yielding 99.5 ± 0.5% absolute purity, before establishing the standard curve—otherwise, potency overestimation exceeding 15% propagates into cellular EC50 calculations in HUVEC tube-formation assays.
| Solvent | Class | Acceptable Daily Intake (mg/day) | Test Method | Release Limit (ppm) |
|---|---|---|---|---|
| N,N-Dimethylformamide | 2 | 8.8 | Headspace GC-FID, USP <467> Procedure A | 880 |
| Acetonitrile | 2 | 4.1 | Headspace GC-FID, USP <467> Procedure A | 410 |
| Dichloromethane | 2 | 6.0 | Headspace GC-MS | 600 |
| Ethyl Acetate | 3 | 50 | Direct Injection GC-FID | 5,000 |
| Tetrahydrofuran | 2 | 7.2 | Headspace GC-FID, USP <467> Procedure B | 720 |
Co-crystallization with succinic acid through liquid-assisted grinding (LAG) employing a Retsch MM400 mixer mill at 25 Hz for 30 minutes with acetonitrile added at η = 0.3 µL/mg has been reported to produce a 1:1 co-crystal characterized by a unique PXRD reflection at 2θ = 6.8° absent in the parent Form I. This co-crystal elevates intrinsic dissolution rate to 0.084 mg·cm⁻²·min⁻¹ in biorelevant FaSSIF media, bypassing the solubility-limited absorption that restricts oral bioavailability of the free base to approximately 21% in fasted beagle models. Manufacturing scale-up using a continuous oscillatory baffled reactor (COBR) with residence time fixed at 8 minutes, oscillation frequency of 2.0 Hz, and amplitude of 10 mm yielded co-crystal purity >97% by Raman mapping at a throughput of 50 g/h. In contrast, thermal co-crystallization via Kofler hot-stage methodology results in partial disproportionation above 160 °C, making solvent-free continuous extrusion the preferred method. Particle size reduction for the co-crystal was performed via jet milling at a Venturi pressure of 4.5 bar and ring pressure of 3.0 bar, generating a D90 of 35 µm suitable for capsule filling without altering stoichiometry as validated by solid-state 13C CP-MAS NMR integration ratios.
Deployment of the compound as a covalent inhibitor warhead precursor in structure-based drug design for BTK or YES1 kinase templates requires derivatization of the N-2-hydroxypropylmorpholine side chain with acryloyl chloride under anhydrous dichloromethane at 0 °C, catalyzed by triethylamine at 1.2 molar equivalents. The resulting acrylamide-functionalized probe retains IC50 < 1.0 nM against its primary target but exhibits time-dependent inactivation kinetics with kinact/KI = 0.052 min⁻¹·µM⁻¹ as determined by jump-dilution assays. GSH reactivity screening at 5.0 mM glutathione in PBS pH 7.4 reveals 12% adduct formation over 30 minutes, categorizing the probe as low intrinsic reactivity suitable for in-vivo proteomics (isoTOP-ABPP platforms). This derivative is not isolated as a purified intermediate; rather, the raw alkene-containing precursor is delivered at ≥ 97.0% area purity with residual acryloyl chloride below 5.0 ppm as a duty-of-care specification—amide pronucleophiles react with even trace levels to form quaternary ammonium byproducts that occlude the active site in crystallography soaking experiments. Storage of the solid intermediate at -20 °C under argon in septum-capped amber vials prevents premature Michael addition of nucleophilic impurities originating from air.
